Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 25 |
| Active Pipeline (Recruiting Now) | 14 (8) |
| Completed vs Stopped Early | 3 / 7 (28.0%) |
| Median Closed Actual Enrollment | 59 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| CHU de Nantes | Nantes | 3 |
| Institut Gustave Roussy | Villejuif | 3 |
| CHU d'Angers | Angers | 3 |
Explore interactive annual charts and M&A subsidiary rollups in the University Hospital, Montpellier Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.